N@N

Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, Februar

_{//health-fitness.news-articles.net/content/2013/ .. e-presentation-scheduled-for-monday-februar.html}
^{Published in Health and Fitness on Friday, February 8th 2013 at 5:46 GMT by Market Wire}  

Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor... -- NEW YORK, Feb. 8, 2013 /PRNewswire/ --

NEW YORK, Feb. 8, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: [ KERX ]) today announced that Ron Bentsur , the Company's Chief Executive Officer, will be presenting at the 15th Annual BIO CEO & Investor Conference, being held February 11-12, 2013, in New York City.  Mr. Bentsur's presentation is scheduled to take place on Monday, February 11^th, at 2:30 PM ET. 

A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at [ http://investors.keryx.com ]. An archived version of the webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has completed a U.S.-based Phase 3 clinical program for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA, and Keryx expects to submit an NDA with the FDA and a MAA with the EMA in the second quarter of 2013.  Zerenex is also in Phase 2 development in the U.S. for the management of phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease.  In addition, Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has filed its New Drug Application for marketing approval of ferric citrate in Japan for the treatment of hyperphosphatemia in patients with chronic kidney disease.  Keryx is headquartered in New York City. 

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: [ lfischer@keryx.com ]

SOURCE Keryx Biopharmaceuticals, Inc.